Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Novo Nordisk (NYSE:NVO) A/S, the Danish pharmaceutical giant valued at $361.6 billion, has been making waves in the healthcare sector with its groundbreaking treatments for diabetes and obesity.

Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...